Skip to Content

Treprostinil Disease Interactions

There are 7 disease interactions with treprostinil:

Major

Treprostinil (applies to treprostinil) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C). There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients. It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).

Moderate

Treprostinil (applies to treprostinil) bleeding

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect

Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding. Close monitoring is recommended when using this agent in patients with bleeding disorders.

Moderate

Treprostinil (applies to treprostinil) diverticulosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diverticulitis

The tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulosis. Care should be exercised when using this drug in patient with diverticulosis.

Moderate

Treprostinil (applies to treprostinil) hypotension

Moderate Potential Hazard, Moderate plausibility.

Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with treprostinil injection may produce symptomatic hypotension. Care should be exercised when using this agent in patients at risk.

Moderate

Treprostinil (applies to treprostinil) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Severe hepatic impairment (Child Pugh Class C) is a contraindication in patients taking the oral presentation of treprostinil. Treprostinil is substantially metabolized by the liver, primarily by CYP450 2C8. Treprostinil injection clearance is reduced in patients with hepatic insufficiency. In patients with mild or moderate hepatic insufficiency, decrease the initial dose of treprostinil injection to 0.625 ng/kg/min ideal body weight, and monitor closely. Treprostinil injection has not been studied in patients with severe hepatic insufficiency. It is recommended to titrate treprostinil injection slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.

Moderate

Treprostinil (applies to treprostinil) pulmonary infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

The efficacy of treprostinil inhalant has not been established in patients with significant underlying lung disease. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.

Moderate

Treprostinil (applies to treprostinil) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Treprostinil and its metabolites are excreted mainly through the urinary route. It is recommended to titrate treprostinil injection slowly in patients with renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal renal function. No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis.

Treprostinil drug interactions

There are 302 drug interactions with treprostinil

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.